Bladder Cancer Market: By Type (Transitional Cell Carcinoma, Invasive Bladder Cancer), by Treatment (Chemotherapy, Radiation Therapy, Immunotherapy), by Diagnosis (Urine Lab Tests, Imaging Test), by End-User (Hospital, Clinic) - Global Forecast to 2030

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Bladder cancer Market, by Type

6.1 Introduction

6.2 Transitional Cell Carcinoma

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Invasive Bladder Cancer

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Superficial Bladder Cancer

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 Adenocarcinomax

6.5.1 Market Estimates & Forecast, 2020-2027

6.6 Other rare types

Chapter 7. Global Bladder Cancer Market, by Treatment

7.1 Introduction

7.2 Chemotherapy

7.2.1 Market Estimates & Forecast, 2020-2027

7.2.2 Valstar (valrubicin)

7.2.2.1 Market Estimates & Forecast, 2020-2027

7.2.3 Javlor (vinflunine ditartrate),

7.2.3.1 Market Estimates & Forecast, 2020-2027

7.2.4 Mitomycin C

7.2.4.1 Market Estimates & Forecast, 2020-2027

7.2.5 Gemcitabine and cisplatin chemotherapy (GemCis)

7.2.5.1 Market Estimates & Forecast, 2020-2027

7.2.6 Others

7.3 Radiation Therapy

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Immunotherapy

7.4.1 Market Estimates & Forecast, 2020-2027

7.5 Radical Cystectomy

7.5.1 Market Estimates & Forecast, 2020-2027

7.6 Other

Chapter 8. Global Bladder Cancer Market, by Diagnosis

8.1 Introduction

8.2 Urine Lab Tests

8.2.1 Market Estimates & Forecast, 2020-2027

8.2.2 Urinalysis

8.2.2.1 Market Estimates & Forecast, 2020-2027

8.2.3 Urine Cytology

8.2.3.1 Market Estimates & Forecast, 2020-2027

8.2.4 Urine Culture

8.2.4.1 Market Estimates & Forecast, 2020-2027

8.2.5 Urine Tumor Marker Test

8.2.5.1 Market Estimates & Forecast, 2020-2027

8.3 Cystoscopy

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Biopsy

8.4.1 Market Estimates & Forecast, 2020-2027

8.4 Imaging Test

8.4.1 Market Estimates & Forecast, 2020-2027

8.4.2 Intravenous Pyelogram (IVP)

8.4.2.1 Market Estimates & Forecast, 2020-2027

8.4.3 Computed Tomography (CT) scan

8.4.3.1 Market Estimates & Forecast, 2020-2027

8.4.4 Magnetic Resonance Imaging (MRI) Scan

8.4.4.1 Market Estimates & Forecast, 2020-2027

8.4.5 Bladder Ultrasound

8.4.5.1 Market Estimates & Forecast, 2020-2027

8.5 Other

Chapter 9. Global Bladder Cancer Market, by End Users

9.1 Introduction

9.2 Hospital

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Clinic

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Cancer Care Centers

9.4.1 Market Estimates & Forecast, 2020-2027

9.5 Other

Chapter 10 Company Profiles

10.1 AstraZeneca plc.

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials

10.1.4 SWOT Analysis

10.2 Bristol-Myers Squibb Company

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Celgene Corporation.

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Eli Lilly and Company.

10.4.1 Company Overview

10.4.2 Product/Business Segment Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 F. Hoffmann-La Roche AG

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.6 GlaxoSmithKline plc.

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.7 Novartis International AG

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Pfizer Inc.

10.8.1 Company Overview

10.8.2 Product/Business Segment Overview

10.8.3 Financial Overview

10.8.4 Key Development

10.8.5 SWOT Analysis

10.9 Swastika international Co.

10.9.1 Company Overview

10.9.2 Product Overview

10.9.3 Financial overview

10.9.4 Key Developments

10.10 Stanley Black & Decker

10.10.1 Company Overview

10.10.2 Product Overview

10.10.3 Financial overview

10.10.4 Key Developments

10.11 Celgene Corporation.

10.11.1 Company Overview

10.11.2 Product Overview

10.11.3 Financial overview

10.11.4 Key Developments

10.12 Others

Chapter 11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEO’s View Point

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Prediction of Pharmaceutical industry

Chapter 12 Appendix

LIST OF TABLES

Table 1 Bladder cancer Industry Synopsis, 2020-2027

Table 2 Bladder cancer Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Bladder cancer Market by Region, 2020-2027, (USD Million)

Table 4 Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 5 Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 6 Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 7 Bladder cancer Market by End Users, 2020-2027, (USD Million)

Table 8 North America Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 9 North America Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 10 North America Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 11 North America Bladder cancer Market by End User, 2020-2027, (USD Million)

Table 12 US Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 13 US Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 14 US Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 15 US Bladder cancer Market by End User, 2020-2027, (USD Million)

Table 16 Canada Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 17 Canada Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 18 Canada Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 19 Canada Bladder cancer Market by End User, 2020-2027, (USD Million)

Table 20 South America Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 21 South America Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 22 South America Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 23 South America Bladder cancer Market by End User, 2020-2027, (USD Million)

Table 24 Europe Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 25 Europe Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 26 Europe Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 27 Europe Bladder cancer Market by End User, 2020-2027, (USD Million)

Table 28 Western Europe Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 29 Western Europe Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 30 Western Europe Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 31 Western Europe Bladder cancer Market by End User, 2020-2027, (USD Million)

Table 32 Eastern Europe Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 33 Eastern Europe Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 34 Eastern Europe Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 35 Eastern Europe Bladder cancer Market by End User, 2020-2027, (USD Million)

Table 36 Asia Pacific Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 37 Asia Pacific Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 38 Asia Pacific Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 39 Asia Pacific Bladder cancer Market by End User, 2020-2027, (USD Million)

Table 40 The Middle East & Africa Bladder cancer Market by Type, 2020-2027, (USD Million)

Table 41 The Middle East & Africa Bladder cancer Market by Treatment, 2020-2027, (USD Million)

Table 42 The Middle East & Africa Bladder cancer Market by Diagnosis, 2020-2027, (USD Million)

Table 43 The Middle East & Africa Bladder cancer Market by End User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Bladder cancer Market

Figure 3 Segmentation Market Dynamics for Bladder cancer Market

Figure 4 Global Bladder cancer Market Share, by Type 2020

Figure 5 Global Bladder cancer Market Share, by Treatment 2020

Figure 6 Global Bladder cancer Market Share, by Diagnosis 2020

Figure 7 Global Bladder cancer Market Share, by End-User 2020

Figure 8 Global Bladder cancer Market Share, by Region, 2020

Figure 9 Americas Bladder cancer Market Share, by Country, 2020

Figure 10 Europe Bladder cancer Market Share, by Country, 2020

Figure 11 Asia Pacific Bladder cancer Market Share, by Country, 2020

Figure 12 Middle East & Africa Bladder cancer Market Share, by Country, 2020

Figure 13 Global Bladder cancer Market: Company Share Analysis, 2020 (%)

Figure 14 AstraZeneca plc: Key Financials

Figure 15 AstraZeneca plc: Segmental Revenue

Figure 16 AstraZeneca plc: Geographical Revenue

Figure 17 Bristol-Myers Squibb Company: Key Financials

Figure 18 Bristol-Myers Squibb Company: Segmental Revenue

Figure 19 Bristol-Myers Squibb Company: Geographical Revenue

Figure 20 Celgene Corporation.: Key Financials

Figure 21 Celgene Corporation.: Segmental Revenue

Figure 22 Celgene Corporation.: Geographical Revenue

Figure 23 Eli Lilly and Company: Key Financials

Figure 24 Eli Lilly and Company: Segmental Revenue

Figure 25 Eli Lilly and Company: Geographical Revenue

Figure 26 F. Hoffmann-La Roche AG: Key Financials

Figure 27 F. Hoffmann-La Roche AG: Segmental Revenue

Figure 28 F. Hoffmann-La Roche AG: Geographical Revenue

Figure 29 GlaxoSmithKline plc: Key Financials

Figure 30 GlaxoSmithKline plc: Segmental Revenue

Figure 31 GlaxoSmithKline plc: Geographical Revenue

Figure 32 Novartis International AG: Key Financials

Figure 33 Novartis International AG: Segmental Revenue

Figure 34 Novartis International AG: Geographical Revenue

Figure 35 Pfizer Inc.: Key Financials

Figure 36 Pfizer Inc.: Segmental Revenue

Figure 37 Pfizer Inc.: Geographical Revenue